Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer. This is an ASCO Meeting Abstract from the 2017 Genitourinary Cancers Symposium.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback